Photodynamic Therapy for Early Head and Neck Tumors
|ClinicalTrials.gov Identifier: NCT01019954|
Recruitment Status : Completed
First Posted : November 24, 2009
Last Update Posted : November 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Tumors||Drug: Levulan||Phase 1|
The primary objectives of the study are to evaluate the toxicities associated with Levulan®-mediated photodynamic therapy in pre-malignant head and neck lesions, and to evaluate the toxicities of continuous vs. fractionated light treatment. The secondary objectives are to assess the efficacy of Levulan®-mediated photodynamic therapy in pre-malignant head and neck lesions, and to assess the efficacy of fractionated versus continuous light treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Official Title:||Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
- PDT related toxicity.
- lesion response.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01019954
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|